BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Apr 04, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

MSDC-0602: Phase IIa started

Metabolic Solutions began a double-blind, placebo-controlled, U.S. Phase IIa trial to compare 100, 250 and 500 mg oral MSDC-0602 once daily vs. Actos pioglitazone for 28...

Read the full 117 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >